Follow the people · Insider

EL

Erick Lucera

Insider · Chief Financial Officer · DYN

Erick Lucera files insider transactions with the SEC as a chief financial officer of Dyne Therapeutics (DYN). We hold 4 disclosed purchases and sales filed since 27 March 2017, 2 of them in the last 90 days.

  • Files forDYN
  • Disclosed buys and sells4 in all, 2 in the last 90 days
  • Last disclosure17 August 2026

Positions held

8 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 31 March 202513 August 2026Chief Financial Officer · Dyne Therapeutics (DYN)10 Form 4 lines · source: SEC Form 4
  • Filed 3 April 202316 December 2025Director · SAB Biotherapeutics (SABS)3 Form 4 lines · source: SEC Form 4
  • Filed 16 February 20214 November 2025Director · Beyond Air (XAIR)39 Form 4 lines · source: SEC Form 4
  • Filed 17 May 20238 March 2025EVP, Chief Financial Officer · Editas Medicine (EDIT)9 Form 4 lines · source: SEC Form 4
  • Filed 26 October 202118 September 2023Director · Bone Biologics (BBLG)4 Form 4 lines · source: SEC Form 4
  • Filed 6 January 202019 January 2023Chief Financial Officer · Aveo Pharmaceuticals (AVEO)6 Form 4 lines · source: SEC Form 4
  • Filed 23 March 20177 March 2019Officer · Valeritas Holdings (VLRX)7 Form 4 lines · source: SEC Form 4
  • Filed 16 February 201813 August 2018Director · AIT Therapeutics (AITB)5 Form 4 lines · source: SEC Form 4

Everything they disclosed

83 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.